Recent briefings through late June 2026 did not identify discrete Pfizer-specific corporate news events in the 30 days preceding this report's generation date of 2026-08-04. The broader macro environment over this period was characterised by heightened geopolitical uncertainty, which formed the backdrop against which PFE's operational and financial data was reviewed. No material company-level announcements, such as pipeline readouts, litigation settlements, or strategic transactions, were captured in the briefing record during this window [Brief - 2026-07-27] [Brief - 2026-07-19] [Brief - 2026-07-11].
Pfizer's trailing twelve-month revenue stood at $63.32 billion as of the most recent filing date, representing year-over-year growth of 5.37%. Net income for the same period was $7.49 billion, producing a net margin of 11.83%. Operating margin was recorded at 35.40%. Earnings per share declined 9.62% year-over-year. The company held $1.70 billion in cash against total debt of $64.46 billion, resulting in a net debt position. The price-to-earnings ratio was 19.11 at the time of filing [SEC 10-Q - PFE - 2026-03-29].
Institutional ownership data reflects material position changes across several prominent filers. Citadel reduced its PFE position by 17%, while AQR Capital added 21% to its existing holding and Millennium Management increased its position by 9.9%. These divergent moves across quantitative and multi-strategy firms constitute the primary trigger for this report's generation [SEC 13F - Citadel - Q2 2026] [SEC 13F - AQR Capital - Q2 2026] [SEC 13F - Millennium - Q2 2026].
The 10-year US Treasury yield stood at 4.75% and the 2-year yield at 4.28% at the time of this report, reflecting a normal yield curve configuration with a spread of 47 basis points [FRED DGS10] [FRED DGS2]. This interest rate environment is relevant context for a company carrying $64.46 billion in total debt, as prevailing borrowing costs affect refinancing dynamics across large-cap pharmaceutical issuers.